BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will be presenting at the BofA Securities 2024 Healthcare Conference on May 15, 2024, in Las Vegas, NV.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will be presenting at the BofA Securities 2024 Healthcare Conference on May 15, 2024, in Las Vegas, NV. Alexander Hardy, President, and CEO of BioMarin, will be presenting at 10:00am PT / 1:00pm ET. The presentation will be available via live audio webcast and archived on the company's website.
Details
News Market Reaction – BMRN
The recorded move for BMRN in the trading session of this news was -0.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-bofa-securities-2024-health-care-conference-on-wednesday-may-15-at-1000am-pt--100pm-et-in-las-vegas-nv-302139003.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.